Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Decisions in HIV Care: Choosing Initial ART in PWH With Transmitted Drug Resistance

Listen as John D. Baxter, MD, shares the latest data and recommendations for initiating ART in patients with transmitted antiretroviral drug resistance.
John D. Baxter, MD
Released: January 25, 2022

In this episode, John D. Baxter, MD, explores recommendations and data on choosing antiretroviral therapy with transmitted drug resistance.

Listen as he gives his perspectives on:
  • Initial response to antiretroviral therapy during primary HIV infection with baseline resistance
  • Data from the START study on treatment-naive patients with transmitted drug resistance by region and drug class
  • Recommendations from the US Department of Health and Human Services and International AIDS Society–USA guidelines on baseline genotype testing for integrase strand transfer inhibitor resistance
  • Considerations for the use of second-generation integrase strand transfer inhibitors and darunavir with transmitted drug resistance
  • Cases of transmitted multidrug-resistant HIV in patients receiving pre-exposure prophylaxis

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Information on this Educational Activity

Faculty

John D. Baxter, MD

Professor of Medicine
Division of Infectious Diseases
Department of Pathology
Cooper Medical School of Rowan University
Head, Division of Infectious Diseases
Cooper University Health Care
Camden, New Jersey

John D. Baxter, MD, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Listen to expert faculty discuss strategies to promote ART safety and tolerability in aging patients and populations with cardiometabolic toxicities, from Clinical Care Options (CCO)

Marta Boffito, MD, PhD, FRCP Jens D. Lundgren, MD, DMSc Released: January 17, 2023

Dr Christine Katlama discusses minimizing ART exposure with dual-therapy and intermittent dosing strategies, from Clinical Care Options (CCO)

person default Christine Katlama, MD Released: January 4, 2023

Listen to Dr Princy Kumar discuss strategies on selecting between first-line ART regimens in treatment-naïve PWH, from Clinical Care Options (CCO)

Princy N. Kumar, MD, FIDSA, MACP Released: December 29, 2022

Expert HIV faculty analyze new data from AIDS 2022, from Clinical Care Options (CCO)

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, AGPCNP-BC, ACRN, FAANP, FAAN, AAHIVS
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Princy N. Kumar, MD, FIDSA, MACP person default Mary W. Montgomery, MD David A. Wohl, MD
Physicians: maximum of 1.5 AMA PRA Category 1 Credits Registered Nurses: 1.5 Nursing contact hours Pharmacists: 1.5 contact hours (0.15 CEUs) Released: December 23, 2022 Expired: December 22, 2023

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings